{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hosoya H"],"funding":["NCATS NIH HHS","National Institutes of Health"],"pagination":["183-191"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8715952"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(2)"],"pubmed_abstract":["<h4>Purpose of review</h4>The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.<h4>Recent findings</h4>Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring "],"journal":["Current hematologic malignancy reports"],"pubmed_title":["Antibody-Based Treatment Approaches in Multiple Myeloma."],"pmcid":["PMC8715952"],"funding_grant_id":["KL2 TR003143","KL2TR003143, KL2 Mentored Career Development Program, Stanford Clinical Translational Science Award Program"],"pubmed_authors":["Sidana S","Hosoya H"],"additional_accession":[]},"is_claimable":false,"name":"Antibody-Based Treatment Approaches in Multiple Myeloma.","description":"<h4>Purpose of review</h4>The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma.<h4>Recent findings</h4>Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-04T23:02:46.202Z","creation":"2025-04-04T23:02:46.202Z"},"accession":"S-EPMC8715952","cross_references":{"pubmed":["33730360"],"doi":["10.1007/s11899-021-00624-6"]}}